|Bid||128.96 x 800|
|Ask||128.98 x 800|
|Day's Range||127.75 - 129.19|
|52 Week Range||96.70 - 132.49|
|PE Ratio (TTM)||48.86|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||130.23|
This article is intended for those of you who are at the beginning of your investing journey and want to learn about Return on Equity using a real-life example. CharlesRead More...
Charles River Laboratories International, Inc. announced today that it will present at three upcoming investor conferences, including:
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
Charles River (CRL) delivered earnings and revenue surprises of 10.96% and 2.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Wilmington, Massachusetts-based company said it had profit of $1.10. Earnings, adjusted for one-time gains and costs, came to $1.62 per share. The results beat Wall Street expectations. ...
Tenet Healthcare (THC) is likely to repeat its success story in Q2 on the back of a strong performance at the Conifer segment as well as its key initiatives.
NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Myriad ...
Charles River Laboratories International, Inc. (CRL) will release second-quarter 2018 financial results on Wednesday, August 8th, before the market opens. Charles River will host a Meeting with Management on Tuesday, August 14th, from 8:00 a.m. to 12:30 p.m. ET. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
How far off is Charles River Laboratories International Inc (NYSE:CRL) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether theRead More...
Charles River Laboratories Intl. Inc (NYSE: CRL ), a preclinical and clinical laboratory service provider to the pharmaceutical , medical device and biotechnology industries, is "by far" an industry ...
Charles River Laboratories International, Inc. (CRL) announced today that it will present at the Jefferies 2018 Global Healthcare Conference in New York, New York, on Wednesday, June 6th, at 11:00 a.m. ET, and at the William Blair 38th Annual Growth Stock Conference in Chicago, Illinois, on Wednesday, June 13th, at 10:00 a.m. CT (11:00 a.m. ET). Management will present an overview of Charles River’s strategic focus and business developments. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com.
NEW YORK , May 29, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...
The Wilmington, Massachusetts-based company said it had net income of $1.08 per share. Earnings, adjusted for amortization costs and non-recurring costs, were $1.38 per share. The results exceeded Wall ...
Charles River Laboratories International, Inc. today reported its results for the first quarter of 2018. For the quarter, revenue from continuing operations was $494.0 million, an increase of 10.8% from $445.8 million in the first quarter of 2017.
Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced an extension of its long-standing collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinson’s disease (PD). Since 2011, Charles River and MJFF have worked together to accelerate the discovery of therapies for PD. With MJFF support, Charles River has launched a new project, focused on in vivo phenotyping of an α-synuclein knockout model and an α-synuclein A53T knockin model.
Charles River Laboratories International, Inc. today announced the expansion of its service capabilities in early discovery screening. Charles River is the first contract research organization to offer clients access to Apricot Designs' Dual Arm system for high-throughput absorption, distribution, metabolism, and excretion to identify potential lead compounds in North America and Europe.